S-Ruxolitinib (INCB018424)
如果您对该产品感兴趣的话,可以
产品名称:
S-Ruxolitinib (INCB018424)
产品型号:
GOY-Y3754
产品展商:
谷研
产品文档:
无相关文档
发布时间:2023-05-09
简单介绍
S-Ruxolitinib (INCB018424)≥ 100 mg/mL in DMSO
S-Ruxolitinib (INCB018424)
的详细介绍
性能参数
|
产品名称
|
S-Ruxolitinib (INCB018424)
|
规格
|
5mg 10mg 50mg 200mg
|
货号
|
GOY-Y3754
|
含量
|
>98.00%
|
CAS
|
941685-37-6
|
别名
|
S-Ruxolitinib; INCB18424
|
|
|
化学名
|
(3S)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
|
分子式
|
C17H18N6
|
分子量
|
分子量 306.37
|
溶解度
|
≥ 100 mg/mL in DMSO
|
储存条件
|
Store at -20°C
|
General tips
|
|
用途
|
仅供科研
|
价格
|
电询
|
|
详细内容
|
S-Ruxolitinib is the chirality of INCB018424, is a potent and selective small-molecule Janus kinase 1 (JAK1) and JAK2 inhibitor. It was initially developed to target the constitutive activation of the JAK-STAT pathway. Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases that mediates signals from the receptors for various cytokines and growth factors that have a key role in haematopoiesis and immune function. Ruxolitinib maintains its anti-JAK activity by competitive inhibition of the ATP-binding catalytic site of the kinase domain. Ruxolitinib is well absorbed at >95%. Exposure of JAK2V617F-positive Ba/F3 cells to ruxolitinib iss shown to result in reduced cellular proliferation.
|
公司正在销售的产品:
甲氧胺 67-62-9 7-羧基-1H-吲唑 677304-69-7
2-氨基环己醇 6850-38-0 (1R,2R)-(-)-N,N'-二甲基-1,2-环己二胺 68737-65-5
二乙烯基苯与磺化(苯乙烯和乙烯基乙苯)的聚合物 69011-20-7 3-氟氮杂环丁烷盐酸盐 690257-76-2
4-甲基-1-戊烯 691-37-2 6-氨基吡啶-2-羧酸乙酯 69142-64-9
2-溴苯甲酸乙酯 6091-64-1 2-甲氧基苯甲醇 612-16-8
3-氨基-5
|
2′-脱氧鸟苷-5′-...2′-Deoxyguanosine 5′-monophosphate d...33430-61-4250MG
2′-脱氧肌苷2′-Deoxyinosine,≥98%890-38-0100MG
2′-脱氧肌苷-5′-...2′-Deoxyinosine 5′-monophosphate sod...14999-52-15MG
2′-脱氧胸苷-5′-...Thymidine 5′-monophosphate disodium s...33430-62-5100MG
2′-脱氧胸苷-5′-...Thymidine 5′-triphosphate sodium salt...18423-43-3100MG
|